SOFIE Biosciences doses first patient in Phase 3 trial of novel cancer imaging agent
The study will run across 18 sites and enroll roughly 200 patients over 24 months
The study will run across 18 sites and enroll roughly 200 patients over 24 months
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
Using a combination of blood and faecal samples, the service examines key biomarkers, including hereditary genetic status
The cobas Mass Spec solution Ionify reagent portfolio now covers therapeutic drug monitoring for immunosuppressants and antibiotics
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
Subscribe To Our Newsletter & Stay Updated